Biosolution Co.Ltd Total Assets
Biosolution Co.Ltd total assets. Based on the latest financial reports, Biosolution Co.Ltd (086820) holds total assets worth ₩62.56 Billion KRW (≈ $42.40 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 086820 company net worth for the company's overall valuation and market capitalisation.
Total Assets of Biosolution Co.Ltd (2015–2024)
Total assets of Biosolution Co.Ltd from 2015 to 2024. This chart illustrates how Biosolution Co.Ltd's total assets have evolved over time, based on quarterly financial data. See Biosolution Co.Ltd (086820) stock price for real-time trading data and today's change.
Biosolution Co.Ltd - Asset Composition Analysis
Biosolution Co.Ltd Total Assets Breakdown (December 2024)
Biosolution Co.Ltd total assets breakdown as of December 2024. Biosolution Co.Ltd's total assets of ₩62.56 Billion consist of 31.1% current assets and 68.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩12.92 Billion | 19.2% |
| Accounts Receivable | ₩4.64 Billion | 6.9% |
| Inventory | ₩1.49 Billion | 2.2% |
| Property, Plant & Equipment | ₩6.45 Billion | 9.6% |
| Intangible Assets | ₩3.59 Billion | 5.3% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Biosolution Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Biosolution Co.Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biosolution Co.Ltd's current assets represent 31.1% of total assets in 2024, a decrease from 70.6% in 2015.
- Cash Position: Cash and equivalents constituted 19.2% of total assets in 2024, up from 14.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, unchanged from 5.0% in 2015.
- Asset Diversification: The largest asset category is cash and equivalents at 19.2% of total assets.
Biosolution Co.Ltd Competitors by Total Assets
Key competitors of Biosolution Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Biosolution Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.55 | 0.65 | 20.14 |
| Quick Ratio | 0.50 | 0.60 | 19.48 |
| Cash Ratio | 0.00 | 0.26 | 0.00 |
| Working Capital | ₩-15.52 Billion | ₩-11.63 Billion | ₩38.67 Billion |
Biosolution Co.Ltd - Advanced Valuation Insights
This section examines the relationship between Biosolution Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.97 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -26.9% |
| Total Assets | ₩67.46 Billion |
| Market Capitalization | $82.58 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biosolution Co.Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Biosolution Co.Ltd's assets decreased by 26.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biosolution Co.Ltd (2015–2024)
The table below shows the annual total assets of Biosolution Co.Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩67.46 Billion ≈ $45.72 Million |
-26.95% |
| 2023-12-31 | ₩92.35 Billion ≈ $62.58 Million |
+0.67% |
| 2022-12-31 | ₩91.73 Billion ≈ $62.16 Million |
-2.83% |
| 2021-12-31 | ₩94.40 Billion ≈ $63.98 Million |
+89.57% |
| 2020-12-31 | ₩49.80 Billion ≈ $33.75 Million |
-3.88% |
| 2019-12-31 | ₩51.81 Billion ≈ $35.11 Million |
-2.00% |
| 2018-12-31 | ₩52.87 Billion ≈ $35.83 Million |
+616.54% |
| 2017-12-31 | ₩7.38 Billion ≈ $5.00 Million |
-16.36% |
| 2016-12-31 | ₩8.82 Billion ≈ $5.98 Million |
-9.99% |
| 2015-12-31 | ₩9.80 Billion ≈ $6.64 Million |
-- |
About Biosolution Co.Ltd
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2… Read more